SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
136 hedge funds and large institutions have $2.79B invested in SpringWorks Therapeutics in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 22 closing their positions.
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
12% more call options, than puts
Call options by funds: $33.6M | Put options by funds: $29.9M
7.93% more ownership
Funds ownership: 92.29% → 100.23% (+7.9%)
1% less capital invested
Capital invested by funds: $2.82B → $2.79B (-$24.9M)
6% less funds holding
Funds holding: 144 → 136 (-8)
36% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$120M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$74.3M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$21.4M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$18.4M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$12.1M |
| 3 |
DM
Deerfield Management
New York
|
-$11.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.9M |
| 5 |
Two Sigma Investments
New York
|
-$4.85M |
SWTX Hedge Fund Activity: Q1 2022 in Review
136 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q1 2022, worth a combined $2.79B — down 0.88% from $2.82B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SWTX and 14 opened new positions — a net loss of 8 holders — while 46 trimmed existing stakes and 52 added.
The largest buyer was Fidelity Investments, adding an estimated $120M. The largest seller was Perceptive Advisors, cutting an estimated $18.4M.
- 136 institutional investors held SpringWorks Therapeutics (SWTX) as of Q1 2022, down from 144 in Q4 2021.
- Funds reported $2.79B of SpringWorks Therapeutics stock for Q1 2022, down 0.88% quarter-over-quarter.
- 14 funds opened new SpringWorks Therapeutics positions in Q1 2022 and 22 closed out, a net change of -8 holders.
- The largest SpringWorks Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $120M added.
- The largest SpringWorks Therapeutics seller in Q1 2022 was Perceptive Advisors, an estimated $18.4M sold.
Based on aggregated 13F filings for Q1 2022.